Drug news
Novartis to discontinue development of long acting Fanapt for Schizophrenia
Novartis Pharma AG is discontinuing development of a long-acting injectable version of Fanapt (iloperidone) reported Vanda Pharmaceuticals in a securities filing.
Novartis has marketed Fanapt, which is Vanda�s lead product, since 2010. Novartis has exclusive rights to develop and commercialize other formulations of Fanapt in the USA and Canada.